Literature DB >> 27053106

Cross-talk between Dopachrome Tautomerase and Caveolin-1 Is Melanoma Cell Phenotype-specific and Potentially Involved in Tumor Progression.

Ioana L Popa1, Adina L Milac2, Livia E Sima3, Petruta R Alexandru3, Florin Pastrama2, Cristian V A Munteanu3, Gabriela Negroiu4.   

Abstract

l-Dopachrome tautomerase (l-DCT), also called tyrosinase-related protein-2 (TRP-2), is a melanoma antigen overexpressed in most chemo-/radiotherapeutic stress-resistant tumor clones, and caveolin-1 (CAV1) is a main regulator of numerous signaling processes. A structural and functional relationship between DCT and CAV1 is first presented here in two human amelanotic melanoma cell lines, derived from vertical growth phase (MelJuSo) and metastatic (SKMel28) melanomas. DCT co-localizes at the plasma membrane with CAV1 and Cavin-1, another molecular marker for caveolae in both cell phenotypes. Our novel structural model proposed for the DCT-CAV1 complex, in addition to co-immunoprecipitation and mass spectrometry data, indicates a possible direct interaction between DCT and CAV1. The CAV1 control on DCT gene expression, DCT post-translational processing, and subcellular distribution is cell phenotype-dependent. DCT is a modulator of CAV1 stability and supramolecular assembly in both cell phenotypes. During autocrine stimulation, the expressions of DCT and CAV1 are oppositely regulated; DCT increases while CAV1 decreases. Sub-confluent MelJuSo clones DCT(high)/CAV1(low) are proliferating and acquire fibroblast-like morphology, forming massive, confluent clusters as demonstrated by immunofluorescent staining and TissueFAXS quantitative image cytometry analysis. CAV1 down-regulation directly contributes to the expansion of MelJuSo DCT(high) subtype. CAV1 involved in the perpetuation of cell phenotype-overexpressing anti-stress DCT molecule supports the concept that CAV1 functions as a tumor suppressor in early stages of melanoma. DCT is a regulator of the CAV1-associated structures and is possibly a new molecular player in CAV1-mediated processes in melanoma.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  antigen processing; caveolin; epithelial-mesenchymal transition (EMT); melanoma; structural model

Mesh:

Substances:

Year:  2016        PMID: 27053106      PMCID: PMC4933476          DOI: 10.1074/jbc.M116.714733

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

Review 1.  Caveolins, liquid-ordered domains, and signal transduction.

Authors:  E J Smart; G A Graf; M A McNiven; W C Sessa; J A Engelman; P E Scherer; T Okamoto; M P Lisanti
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

Review 2.  Differential ER exit in yeast and mammalian cells.

Authors:  Reika Watanabe; Howard Riezman
Journal:  Curr Opin Cell Biol       Date:  2004-08       Impact factor: 8.382

3.  Caveolin-1 hydrophobic segment peptides insertion into membrane mimetic systems: role of proline residue.

Authors:  Satoko Aoki; Richard M Epand
Journal:  Biochim Biophys Acta       Date:  2011-09-17

Review 4.  Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane.

Authors:  T Okamoto; A Schlegel; P E Scherer; M P Lisanti
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

5.  Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes.

Authors:  U Rodeck; K Melber; R Kath; H D Menssen; M Varello; B Atkinson; M Herlyn
Journal:  J Invest Dermatol       Date:  1991-07       Impact factor: 8.551

6.  Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice.

Authors:  Lisa Sevenich; Uta Schurigt; Kathrin Sachse; Mieczyslaw Gajda; Fee Werner; Sebastian Müller; Olga Vasiljeva; Anne Schwinde; Nicole Klemm; Jan Deussing; Christoph Peters; Thomas Reinheckel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-21       Impact factor: 11.205

7.  TRP-2 specifically decreases WM35 cell sensitivity to oxidative stress.

Authors:  Quentin Michard; Stephane Commo; Jean-Philippe Belaidi; Anne-Marie Alleaume; Jean-Francois Michelet; Edwige Daronnat; Joan Eilstein; Daniel Duche; Laurent Marrot; Bruno Alain Bernard
Journal:  Free Radic Biol Med       Date:  2007-12-14       Impact factor: 7.376

8.  E-cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-Tcf/Lef-dependent transcription.

Authors:  Vicente A Torres; Julio C Tapia; Diego A Rodriguez; Alvaro Lladser; Cristian Arredondo; Lisette Leyton; Andrew F G Quest
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

9.  Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase.

Authors:  Brian J Pak; Jane Lee; Boun L Thai; Serge Y Fuchs; Yuval Shaked; Ze'ev Ronai; Robert S Kerbel; Yaacov Ben-David
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

10.  A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization.

Authors:  Libin Liu; Paul F Pilch
Journal:  J Biol Chem       Date:  2007-12-03       Impact factor: 5.157

View more
  3 in total

1.  MiR-382 Functions on the Regulation of Melanogenesis via Targeting dct in Rainbow Trout (Oncorhynchus mykiss).

Authors:  Shenji Wu; Jinqiang Huang; Yongjuan Li; Zhe Liu; Lu Zhao
Journal:  Mar Biotechnol (NY)       Date:  2022-07-27       Impact factor: 3.727

Review 2.  Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy-An Integrated View into Other Neoplasms and Chemokine Networks.

Authors:  Anca Filimon; Iulia A Preda; Adina F Boloca; Gabriela Negroiu
Journal:  Cells       Date:  2021-12-30       Impact factor: 6.600

3.  Low Blue Dose Photodynamic Therapy with Porphyrin-Iron Oxide Nanoparticles Complexes: In Vitro Study on Human Melanoma Cells.

Authors:  Simona Nistorescu; Ana-Maria Udrea; Madalina Andreea Badea; Iulia Lungu; Mihai Boni; Tatiana Tozar; Florian Dumitrache; Valentin-Adrian Maraloiu; Roua Gabriela Popescu; Claudiu Fleaca; Ecaterina Andronescu; Anca Dinischiotu; Angela Staicu; Mihaela Balas
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.